By decorating the surface of nanoparticles with affinity ligands such as tumor-targeting peptides, siRNA therapeutics can be preferentially directed to tumor cells of interest via specific cell surface receptor-ligand interactions. This evidence concerns the gene CD177 and neoplasm.